A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
University of California, Irvine
UNC Lineberger Comprehensive Cancer Center
Canadian Cancer Trials Group
Memorial Sloan Kettering Cancer Center
University of Chicago
University of California, Davis
Montefiore Medical Center
Mayo Clinic
Genentech, Inc.
National Cancer Institute (NCI)
Northwestern University
City of Hope Medical Center
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Roswell Park Cancer Institute
Case Comprehensive Cancer Center